Heather Horne

1.1k citations

31 papers · 795 indexed · h-index 11

Impact in

Pathology and Forensic Medicine top 5%
- Lymphoma Diagnosis and Treatment
Genetics top 5%
- Chronic Lymphocytic Leukemia Research

Papers in

Pathology and Forensic Medicine 19
- Lymphoma Diagnosis and Treatment 18
Genetics 11
- Chronic Lymphocytic Leukemia Research 11

Co-authors: David M. Goldenberg William A. Wegener Rubén Niesvizky John P. Leonard Morton Coleman Franck Morschhauser Asher Chanan‐Khan Edward A. Stadtmauer
Journals: Journal of Clinical Oncology (9 papers)Blood (8 papers)Clinical Cancer Research (2 papers)British Journal of Haematology (2 papers)Haematologica (2 papers)
Partner nations: United States France Sweden

In The Last Decade

Heather Horne

31 papers receiving 775 citations

Peers

Countries citing papers authored by Heather Horne

Since Specialization

Citations

This map shows the geographic impact of Heather Horne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heather Horne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heather Horne more than expected).

Fields of papers citing papers by Heather Horne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heather Horne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heather Horne. The network helps show where Heather Horne may publish in the future.

Co-authors

The 25 scholars most cited alongside Heather Horne, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Heather Horne Line = papers co-authored together Heather Horne links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial UNC Libraries ·Nathan C. Hall, Bert H. O’Neil, Alberto Pravato, Michael J. Guarino, John Kauh, Max W. Sung, Daniel Lee, Elías A. Torres Armas, Kenneth Pennington, Tanios Bekaii‐Saab, Stanley J. Goldsmith, David V. Gold, Heather Horne, David M. Goldenberg, Arif Sheikh, Aldo N. Serafini, William A. Wegener, Alice Cicognani, Alberto J. Montero, Seza A. Güleç	2020	1
2	Abstract OT2-07-05: A phase III, randomized trial of sacituzumab govitecan (IMMU-132) vs treatment of physician choice (TPC) for metastatic triple-negative breast cancer (mTNBC) Cancer Research ·Valérie Agosta-Ives, HS Rugo, Heather Horne, Д. С. Андреев, D M Goldenberg, J. O’Shaughnessy	2018	2
3	Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia Haematologica ·Howard A. Liebman, Mansoor N. Saleh, James B. Bussel, Zahra Saadati, Heather Horne, William A. Wegener, David M. Goldenberg	2016	8
4	CT-01 Phase IB study of IMMU-115 (humanised ANTI-CD74 antibody) targeting antigen presenting cells in patients with systemic lupus erythematosus (SLE) Clinical Trials ·Daniel J. Wallace, William A. Wegener, Heather Horne, David M. Goldenberg	2016	6
5	Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia* Leukemia & lymphoma ·Matt Kalaycio, Zahra Saadati, Steven L. Allen, R. Kanti, Amr Zakaria, Heather Horne, William A. Wegener, David M. Goldenberg	2015	11
6	Phase I, multicentre, dose‐escalation trial of monotherapy with milatuzumab (humanized anti‐CD74 monoclonal antibody) in relapsed or refractory multiple myeloma British Journal of Haematology ·Jonathan L. Kaufman, Rubén Niesvizky, Edward A. Stadtmauer, Asher Chanan‐Khan, David S. Siegel, Heather Horne, William A. Wegener, David M. Goldenberg	2013	92
7	Fractionated radioimmunotherapy with ⁹⁰ Y‐clivatuzumab tetraxetan and low‐dose gemcitabine is active in advanced pancreatic cancer Cancer ·Allyson J. Ocean, Kenneth Pennington, Michael J. Guarino, Arif Sheikh, Tanios Bekaii‐Saab, Aldo N. Serafini, Daniel Lee, Max W. Sung, Seza Güleç, Stanley J. Goldsmith, Alberto Pravato, Michael Holt, Bert H. O’Neil, Nathan C. Hall, Alberto J. Montero, John Kauh, David V. Gold, Heather Horne, William A. Wegener, David M. Goldenberg	2012	64
8	Activity of fractionated radioimmunotherapy (RAIT) with 90Y clivatuzumab tetraxetan (90Y-hPAM4) plus gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results from a two-part study. Journal of Clinical Oncology ·Allyson J. Ocean, Michael J. Guarino, Kenneth Pennington, Gregory M. Springett, Seza A. Güleç, Tanios Bekaii‐Saab, Alberto J. Montero, Edith P. Mitchell, John Kauh, Max W. Sung, David V. Gold, Heather Horne, William A. Wegener, David M. Goldenberg	2012	1
9	Monotherapy with Subcutaneous (SC) Injections of Low Doses of Humanized Anti-CD20 Veltuzumab Is Active in Chronic Lymphocytic Leukemia (CLL) Blood ·Matt Kalaycio, Zahra Saadati, Rebecca Elstrom, Charles M. Farber, Heather Horne, William A. Wegener, David M. Goldenberg	2012	7
10	Phase I/II Study of Monotherapy with Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia Blood ·Howard A. Liebman, Mansoor N. Saleh, James B. Bussel, Zahra Saadati, Heather Horne, William A. Wegener, David M. Goldenberg	2012	1
11	Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial Clinical Cancer Research ·Seza A. Güleç, Steven J. Cohen, Kenneth Pennington, Lionel S. Zuckier, Ralph J. Hauke, Heather Horne, William A. Wegener, kr, David V. Gold, Robert M. Sharkey, David M. Goldenberg	2011	46
12	Phase I/II Study of Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia, Blood ·Howard A. Liebman, Mansoor N. Saleh, James B. Bussel, Zale P. Bernstein, Zahra Saadati, Chen Weiliang, Charles M. Farber, Heather Horne, William A. Wegener, David M. Goldenberg	2011	1
13	Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma Haematologica ·Ramón Márquez Iguarán, Rebecca Elstrom, Steven L. Allen, K. R., Amr Zakaria, Charles M. Farber, kr, Heather Horne, William A. Wegener, David M. Goldenberg	2010	40
14	High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma Journal of Clinical Oncology ·Franck Morschhauser, Françoise Kraeber‐Bodéré, William A. Wegener, Jean‐Luc Harousseau, Marie‐Odile Petillon, D. Huglo, Lorenz Trümper, J. Meller, Michael Pfreundschuh, Carl‐Martin Kirsch, Ralph Naumann, J. Kropp, Heather Horne, kr, Steven Le Gouill, Caroline Bodet‐Milin, Jean‐François Chatal, David M. Goldenberg	2010	78
15	Subcutaneous Injections of Low Doses of Humanized Anti-CD20 Veltuzumab for Treatment of Indolent B-Cell Malignancies. Blood ·Zahra Saadati, Steven L. Allen, R. Kanti, Rebecca Elstrom, Linda Siregar, Charles M. Farber, Nick Teoh, Heather Horne, William A. Wegener, David M. Goldenberg	2009	9
16	Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results Journal of Clinical Oncology ·Franck Morschhauser, John P. Leonard, Luis Fayad, Bertrand Coiffier, Antoine Pédron, Morton Coleman, Stephen J. Schuster, Martin J.S. Dyer, Heather Horne, kr, William A. Wegener, David M. Goldenberg	2009	124
17	Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP). Blood ·Mansoor N. Saleh, Howard A. Liebman, Zale P. Bernstein, Zahra Saadati, James B. Bussel, Chen Weiliang, Charles M. Farber, Linda Siregar, Thomas M. Cosgriff, Kenneth Pennington, Heather Horne, Nick Teoh, M.T. Tuecks, William A. Wegener, David M. Goldenberg	2009	4
18	Rituximab-Relapsing Patients with Non-Hodgkins Lymphoma Respond Even at Lower Doses of Humanized Anti-CD20 Antibody, IMMU-106 (hA20): Phase I/II Results. Blood ·Franck Morschhauser, John P. Leonard, Luis Fayad, Bertrand Coiffier, Stephen J. Schuster, Martin J.S. Dyer, Marie‐Odile Petillon, Morton Coleman, E. M. K. Leovy, Heather Horne, Li Xu, Nick Teoh, William A. Wegener, David M. Goldenberg	2006	6
19	Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab Clinical Cancer Research ·Ola Lindén, Cécilia Hindorf, Eva Cavallin‐Ståhl, William A. Wegener, David M. Goldenberg, Heather Horne, Tomas Ohlsson, Lars Stenberg, Sven‐Erik Strand, Jan Tennvall	2005	71
20	Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma Journal of Clinical Oncology ·John P. Leonard, Morton Coleman, Jamie Ketas, Anita Ramiwati, J. M. Fiore, Richard R. Furman, Rubén Niesvizky, Tsiporah B. Shore, Amy Chadburn, Heather Horne, BEATRIZ CARDOSO MELO, 牛立刚, William A. Wegener, Ivan D. Horak, David M. Goldenberg	2005	133

About Heather Horne

Heather Horne is a scholar working on Pathology and Forensic Medicine, Genetics, Radiology, Nuclear Medicine and Imaging, Hematology and Oncology, having authored 31 papers that have together received 795 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (18 papers), Monoclonal and Polyclonal Antibodies Research (16 papers), Chronic Lymphocytic Leukemia Research (11 papers), Radiopharmaceutical Chemistry and Applications (7 papers), Immunodeficiency and Autoimmune Disorders (6 papers), Pancreatic and Hepatic Oncology Research (5 papers), Platelet Disorders and Treatments (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). The work is most often cited by research in Pathology and Forensic Medicine (403 citations), Genetics (224 citations), Radiology, Nuclear Medicine and Imaging (389 citations), Oncology (355 citations) and Hematology (108 citations). Heather Horne has collaborated with scholars based in United States, France and Sweden. Frequent co-authors include David M. Goldenberg, William A. Wegener, Rubén Niesvizky, John P. Leonard, Morton Coleman, Franck Morschhauser, Asher Chanan‐Khan, Edward A. Stadtmauer, Jonathan L. Kaufman and David S. Siegel. Their work appears in journals such as Journal of Clinical Oncology, Blood, Clinical Cancer Research, British Journal of Haematology and Haematologica.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact